BRD2 and polycystic ovary syndrome: In conclusion, GnRH antagonist protocols should serve as first-line COS protocols for PCOS patients undergoing IVF/ICSI and fresh embryo transfer cycles, but the limited evidence of this study suggests that for PCOS patients with lower bLH/FSH (<1.33) and lower serum AMH levels (≤3.4 ng/ml), follicular phase GnRH agonist protocols may be another safe choice that does not increase severe OHSS risks.